Your heartHealthy livingFor professionalsResearchHow you can helpAbout us

Dr Ying Wang

Research directory


Dr Ying Wang

Improving heart disease in acute kidney injury

Dr Ying Wang, University of New South Wales

2021 Vanguard Grant

Years funded: 2022-2024

Acute kidney injury (AKI) is common in hospital care and rates are increasing. AKI is also common in patients with diabetes, especially in diabetes kidney disease where the incidence of AKI is approximately 30%. Patients with diabetes are at an increased risk of developing cardiovascular and chronic kidney disease (CKD). Patients with AKI are also associated with poor cardiovascular and kidney outcomes. This program explores a strategy to improving cardiovascular outcomes in AKI. Dapagliflozin is a newer glucose lowering agent with cardiovascular and renal benefits in CKD. However, its effects in AKI remain unclear. The DISCOVER study is a pilot multicentre feasibility randomised controlled trial (RCT) to assess the effect of Dapagliflozin on cardiovascular outcomes in patients with diabetes who recovered from AKI, with a view to establishing a large-scale RCT. This project is of great clinical and scientific importance. It will improve patients’ outcomes and save healthcare costs associated with management of long-term outcomes after AKI.

Last updated04 April 2022